CRESCENT BIOPHARMA, INC.
CBIODrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 4 past
No catalysts found.
How CBIO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CR-001 | Phase 2 | Locally Advanced / Metastatic Solid Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CRESCENT BIOPHARMA, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in CRESCENT BIOPHARMA, INC.'s (CBIO) pipeline across Phase 2. Its lead program is CR-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CRESCENT BIOPHARMA, INC.'s next FDA catalyst?→
CRESCENT BIOPHARMA, INC.'s (CBIO) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CBIO biotech catalysts?→
Add CBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CRESCENT BIOPHARMA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.